ArticleCancer letters2026
Reactivating necroptosis in colorectal cancer potentiates chemotherapy and antitumor immune responses.
Article in Cancer letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functional amyloids as molecular switches: emerging roles in diverse signalling pathways.Biochemical Society transactions · 2026Review
- Autophagy Orchestrates Anti-Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP-2 Axis in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Necroptosis, a form of immunogenic cell death (ICD), is frequently impaired in cancer due to the silencing of key regulators, such as RIP3. Despite its potential immunogenic benefits, restoring necroptosis in cancer therapy has been largely underexplored, primarily due to the lack of effective strategies or agents that specifically engage necroptosis without activating apoptosis. In this study, we investigated strategies to restore necroptosis for chemosensitization in RIP3-silenced colorectal cancer (CRC) cells. While reconstituting RIP3 did not impact cell killing by chemotherapy, bypassing RIP3 to induce necroptosis using the natural compound OSW-1 emerged as a promising strategy. OSW-1 displayed strong synergy with 5-fluorouracil (5-FU), effectively eliminating RIP3-silenced CRC cells and tumors through the induction of both necroptosis and apoptosis. Cell death triggered by the OSW-1/5-FU combination was mediated by p53 and CaMKIIδ-driven MLKL phosphorylation, a critical step in the execution of necroptosis. The combination robustly induced ICD hallmarks in CRC cells and immune infiltration in syngeneic tumors. The in vivo antitumor effect of the OSW-1/5-FU combination was largely dependent on antitumor immunity, and abolished by anti-CD8 antibody or immunodeficient hosts. Furthermore, the combination increased immune infiltration in patient-derived primary CRC Air-Liquid Interface (ALI) organoid cultures with autologous immune tumor microenvironment. Collectively, our findings support a novel strategy to activate RIP3-independent necroptosis, providing a compelling rationale to boost the efficacy of chemotherapy via enhanced CRC cell killing and antitumor immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.